首頁 > 市場調查報告書 > 製藥

感染疾病

麴菌症治療市場規模、佔有率和成長分析（按感染類型、藥物類別、給藥途徑、分銷管道、患者類別和地區分類）－2026-2033年產業預測

市場調查報告書

商品編碼

1945694

麴菌症治療市場規模、佔有率和成長分析（按感染類型、藥物類別、給藥途徑、分銷管道、患者類別和地區分類）－2026-2033年產業預測

Aspergillosis Treatment Market Size, Share, and Growth Analysis, By Infection Type, By Drug Class, By Route of Administration, By Distribution Channel, By Patient Category, By Region - Industry Forecast 2026-2033

出版日期: 2026年02月11日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

預計到 2024 年，全球麴菌症治療市場規模將達到 44 億美元，到 2025 年將達到 46.1 億美元，到 2033 年將達到 66.5 億美元，預測期（2026-2033 年）的複合年成長率為 4.7%。

由曲霉菌屬引起的真菌感染疾病日益普遍，尤其是在免疫力缺乏患者中，這促使人們對麴菌症治療方案進行大量投資。侵襲性麴菌症、慢性肺部麴菌症和過敏性支氣管麴菌症等疾病需要及時進行抗真菌治療，這迫使醫療專業人員優先考慮透過提高高風險族群的診斷準確性來進行早期發現和早期療育。這導致對個人化治療方案的需求不斷成長。Azole、Echinocandins和Polyenes等新型抗真菌藥物的持續研發有望透過應對原發性和抗藥性感染來推動市場成長。此外，免疫抑制的增加和器官移植的增加等因素也在影響治療格局，凸顯了在這一重要醫療領域改善患者預後的必要性。

全球麴菌症治療市場按感染類型、藥物類別、給藥途徑、通路、患者群體和地區進行細分。依感染類型分類，可分為過敏性麴菌症、慢性麴菌症及侵襲性麴菌症。依藥物類別分類，可分為抗真菌藥物、皮質類固醇和其他藥物。依給藥途徑分類，可分為口服、靜脈注射、吸入乾粉及其他途徑。按通路分類，可分為醫院藥房、零售藥房和線上藥房。依患者族群分類，可分為造血幹細胞移植患者、固態器官移植患者、ICU/重症監護患者、慢性阻塞性肺病和重症氣喘患者等患者。依地區分類，可分為北美、歐洲、亞太、拉丁美洲以及中東和非洲。

推動全球麴菌症治療市場發展的因素

免疫功能低下患者（包括器官移植受者和接受免疫抑制治療的患者）數量的不斷成長，推動了對有效抗真菌治療和支持性護理的需求。隨著這類患者群體的擴大，醫療機構和醫務人員認知到，快速診斷和穩定的抗真菌藥物供應至關重要。這種認知的提高促使人們更加重視將抗真菌治療納入醫療處方箋，從而導致藥物採購量激增，以確保麴菌症和其他真菌感染疾病高風險患者能夠便捷地獲得有效治療方法。

全球麴菌症治療市場面臨的限制因素

麴菌症抗真菌治療藥物的高昂價格和複雜的採購流程嚴重阻礙了患者的獲得，導致醫療服務提供者即使面臨明顯的臨床需求，也往往不願開立這些必要的治療藥物。醫療支付者和醫療機構面臨的預算限制，常常迫使他們優先選擇價格更低的替代藥物或限制醫保覆蓋範圍，從而限制了新型品牌藥物的使用。這些經濟障礙不僅降低了患者對處方治療的依從性，也阻礙了對創新且昂貴的製劑的投資，最終抑制了整個麴菌症治療市場的成長。

全球麴菌症治療市場趨勢

為因應真菌感染疾病日益普遍的現狀，全球麴菌症治療市場正呈現出標靶治療蓬勃發展的顯著趨勢。這項轉變的特點在於，更加重視開發針對個別患者情況和病原體獨特特徵的客製化治療方案。研究人員正在探索各種新型藥物和老藥新用，以及生物製藥和合併治療策略。許多公司正優先開發差異化產品，並致力於建立強大的藥物研發管線，專注於這些創新療法，以期在對抗麴菌症的鬥爭中改善臨床療效和患者管理。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 墨西哥
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Pfizer, Inc
Merck & Co.
Gilead Sciences, Inc.
Astellas Pharma Inc
Novartis AG
F2G
Cidara Therapeutics, Inc.
Bristol-Myers Squibb
Roche
Bayer AG
Sanofi
Amneal Pharmaceuticals Inc.
Teva Pharmaceutical Industries Ltd
Scynexis, Inc.
Basilea Pharmaceutica Ltd
Hikma Pharmaceuticals plc
Mundipharma Intl Ltd
Mayne Pharma Group Limited
Glenmark Pharmaceuticals Ltd
GlaxoSmithKline plc

結論與建議

簡介目錄

Product Code: SQMIG35I2503

Global Aspergillosis Treatment Market size was valued at USD 4.4 Billion in 2024 and is poised to grow from USD 4.61 Billion in 2025 to USD 6.65 Billion by 2033, growing at a CAGR of 4.7% during the forecast period (2026-2033).

The rising prevalence of fungal infections caused by Aspergillus species, particularly among immunocompromised individuals, is driving significant investment in aspergillosis treatment solutions. Conditions like invasive aspergillosis, chronic pulmonary aspergillosis, and allergic bronchopulmonary aspergillosis necessitate timely antifungal therapy, prompting healthcare professionals to prioritize early detection and intervention through enhanced diagnostics for high-risk populations. As a result, there is a growing demand for tailored therapeutic approaches. The market is poised for growth, fueled by the ongoing development of innovative antifungal agents, including azole compounds, echinocandins, and polyenes, to address both initial and resistant infections. Additionally, factors such as the increasing incidence of immunosuppression and organ transplant procedures further influence the treatment landscape, emphasizing the need for improved patient outcomes in this critical healthcare area.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Aspergillosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Aspergillosis Treatment Market Segments Analysis

Global aspergillosis treatment market is segmented into infection type, drug class, route of administration, distribution channel, patient category and region. Based on infection type, the market is segmented into allergic Aspergillosis, chronic Aspergillosis and invasive Aspergillosis. Based on drug class, the market is segmented into antifungal drugs, corticosteroids and others. Based on route of administration, the market is segmented into oral, intravenous, inhaled dry-powder and others. Based on distribution channels, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy. Based on patient category, the market is segmented into hematopoietic stem-cell transplant, solid-organ transplant, ICU / critical-care patients, COPD & severe asthma patients and others. Based on the region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Driver of the Global Aspergillosis Treatment Market

The rise in individuals with compromised immune systems, such as those who have undergone organ transplants or are on immunosuppressive therapies, is driving the demand for effective antifungal treatments and supportive care. As these patient populations expand, healthcare providers and organizations are recognizing the critical need for prompt diagnosis and the consistent availability of antifungal therapies. This heightened awareness has led to an increased focus on incorporating antifungal treatments into healthcare formularies, resulting in a surge in procurement to ensure that effective solutions are readily accessible for those at heightened risk of Aspergillosis and other fungal infections.

Restraints in the Global Aspergillosis Treatment Market

The accessibility of antifungal treatments for Aspergillosis is significantly hindered by the high costs associated with these medications and the complexities involved in procurement. This situation results in healthcare providers being reluctant to prescribe these essential treatments, even when there is a clear clinical need. Budgetary constraints faced by healthcare payers and institutions often prioritize more affordable alternatives or impose limitations on coverage, which restricts the use of newer or branded medications. These financial barriers not only reduce patient adherence to prescribed therapies but also deter investments in innovative, costly formulations, ultimately stifling the overall growth of the Aspergillosis treatment market.

Market Trends of the Global Aspergillosis Treatment Market

The Global Aspergillosis Treatment market is witnessing a significant trend toward the emergence of targeted therapies, responding to the increasing prevalence of fungal infections. This shift is characterized by a strong emphasis on developing tailored treatment options that cater to individual patient profiles and the unique characteristics of their pathogens. Researchers are exploring a diverse array of novel and repurposed agents, alongside biologic therapies and combination treatment strategies. Numerous companies are prioritizing differentiated product development and maintaining robust drug pipelines focused on these innovative therapeutic approaches, enhancing clinical outcomes and improving patient management in the fight against aspergillosis.

Introduction

Objectives of the Study
Market Definition & Scope

Research Methodology

Research Process
Secondary & Primary Data Methods
Market Size Estimation Methods

Executive Summary

Global Market Outlook
Key Market Highlights
Segmental Overview
Competition Overview

Market Dynamics & Outlook

Macro-Economic Indicators
Drivers & Opportunities
Restraints & Challenges
Supply Side Trends
Demand Side Trends
Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers

Key Market Insights

Key Success Factors
Market Impacting Factors
Top Investment Pockets
Ecosystem Mapping
Market Attractiveness Index, 2025
PESTEL Analysis
Value Chain Analysis
Pricing Analysis
Case Studies
Regulatory Landscape
Technology Assessment
Disease Epidemiology

Global Aspergillosis Treatment Market Size by Infection Type & CAGR (2026-2033)

Market Overview
Allergic Aspergillosis
Chronic Aspergillosis
Invasive Aspergillosis

Global Aspergillosis Treatment Market Size by Drug Class & CAGR (2026-2033)

Market Overview
Antifungal Drugs
- Azoles
- Echinocandins
- Polyenes
- Allylamines
Corticosteroids
Others

Global Aspergillosis Treatment Market Size by Route of Administration & CAGR (2026-2033)

Market Overview
Oral
Intravenous
Inhaled Dry-Powder
Others

Global Aspergillosis Treatment Market Size by Distribution Channel & CAGR (2026-2033)

Market Overview
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy

Global Aspergillosis Treatment Market Size by Patient Category & CAGR (2026-2033)

Market Overview
Hematopoietic Stem-Cell Transplant
Solid-Organ Transplant
ICU / Critical-Care Patients
COPD & Severe Asthma Patients
Others

Global Aspergillosis Treatment Market Size & CAGR (2026-2033)

North America (Infection Type, Drug Class, Route of Administration, Distribution Channel, Patient Category)
- US
- Canada
Europe (Infection Type, Drug Class, Route of Administration, Distribution Channel, Patient Category)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Infection Type, Drug Class, Route of Administration, Distribution Channel, Patient Category)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Infection Type, Drug Class, Route of Administration, Distribution Channel, Patient Category)
- Mexico
- Brazil
- Rest of Latin America
Middle East & Africa (Infection Type, Drug Class, Route of Administration, Distribution Channel, Patient Category)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Pfizer, Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Merck & Co.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Gilead Sciences, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Astellas Pharma Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
F2G
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Cidara Therapeutics, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bristol-Myers Squibb
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Roche
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bayer AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sanofi
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Amneal Pharmaceuticals Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Teva Pharmaceutical Industries Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Scynexis, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Basilea Pharmaceutica Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Hikma Pharmaceuticals plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mundipharma Intl Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Mayne Pharma Group Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Glenmark Pharmaceuticals Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
GlaxoSmithKline plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments